EGFR and incontinentia pigmenti: Their analysis identified a significant elevation in IP in the combination group (25.7%) versus 6.4% for nivolumab alone and 4.6% for EGR TKI alone, suggesting an additive interaction between EGFR TKIs and nivolumab in favor of developing IP.